Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
The ShortCut™ Study Protocol
NCT04952909 · View on ClinicalTrials.gov ↗
Study Summary
A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Clinical Study to Demonstrate the Safety and Effectiveness of the ShortCut™ device for splitting bioprosthetic aortic valve leaflets in patients who are presented for a valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) procedure for an approved ViV indication, and who are at risk for TAVR-induced coronary artery ostium obstruction.
Conditions Studied
Interventions
- DEVICE ShortCut™
Study Locations (20)
Other
- CHU de Bordeaux (Bordeaux University Hospital) — Bordeaux
- Institute Mutualiste Montsouris — Paris
- Clinique Pasteur — Toulouse
- German Heart Institute Berlin — Berlin
- University Hospital Hamburg — Hamburg
- Leipzig Heart Institute — Leipzig
- Sha'are Tzedek Medical Center — Jerusalem
California
- Smidt Heart Institute Cedars-Sinai Medical — Los Angeles
- Kaiser Permanente - San Francisco Medical Center — San Francisco
- Los Robles Regional Medical Center — Thousand Oaks
Arizona
- Tucson Medical Center — Tucson
District of Columbia
- Medstar Washington Hospital Center — Washington D.C.
Illinois
- Advocate Christ Medical Center — Oak Lawn
Michigan
- University of Michigan — Ann Arbor
New Jersey
- Morristown Medical Center — Morristown
New York
- Columbia University Medical Center — New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-01-21 |
| Est. Completion | 2023-12-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04952909
The ClinicalTrials.gov registry entry for NCT04952909 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pi-cardia, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Risk of Coronary Obstruction Following Transcatheter Aortic Valve Replacement (TAVR) Procedure appearing as the primary indexed condition, and to 1 intervention — of which ShortCut™ is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04952909 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Other, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04952909 about?
NCT04952909 is a clinical study titled "The ShortCut™ Study Protocol". A Prospective, Multicenter, Non-Randomized, Single-Arm, Open-Label Clinical Study to Demonstrate the Safety and Effectiveness of the ShortCut™ device for splitting bioprosthetic aortic valve leaflets in patients who are presented for a valve-in-valve (ViV) transcatheter aortic valve replacement (TAV...
What is the current status of trial NCT04952909?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2022-01-21. Estimated completion is 2023-12-31.
What conditions does trial NCT04952909 study?
This clinical trial studies the following conditions: Risk of Coronary Obstruction Following Transcatheter Aortic Valve Replacement (TAVR) Procedure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04952909?
The interventions under investigation include: ShortCut™ (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04952909?
This trial is sponsored by Pi-cardia, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04952909 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.